SIS: Diabetes and CVD in Primary Care: Lasso-up the Latest Guidelines for Best Outcomes! A Patient Case Approach to Integrating the ACC/AHA and ADA/AACE Recommendations

Event Time

Originally Aired - Sunday, May 19 3:00 PM - 5:00 PM

Info Alert

Create or Log in to My Conference Planner to see Videos and Resources.

Info Alert

Your account does not have access to this session.



Create or Log in to My Conference Planner to see Videos and Resources.




Create or Log in to My Conference Planner to see Videos and Resources.

Info Alert

This Session Has Not Started Yet

Be sure to come back after the session starts to have access to session resources.

Event Location

Location: George R. Brown Convention Center, Level 3, 351D

Event Information


A ticket is required for participation in this small interactive session: Register online here.

As of 2019, the ADA reported that over 37 million Americans were living with diabetes and 1.4 million new cases are being added to the tally every year. The CDC reported diabetes as the 8th leading cause of death while the highest cause of death was heart disease.  Based on these numbers, PAs in primary care will undoubtedly care for patients with diabetes, heart disease, or both conditions every day and are uniquely positioned to reduce complications using treatments that improve outcomes. Keeping up with the ever-changing landscape of recommendations from major authorities can be a daunting task. By using real-life case scenarios in this workshop, PAs can navigate new guidelines and arrive at the best care plan for patients with varying degrees of disease, while addressing the health inequities that affect treatment selection.

Learning Objectives:

At the conclusion of this session, participants should be able to:
⦁ Identify patients with, or at high-risk of, diabetes and cardiovascular disease with screening methodologies from the USPSTF and other authorities
⦁ Interpret current diagnostic guidelines for cardiovascular disease from ACC/AHA and diabetes from ADA and the AACE
⦁ Develop individualized treatment plans using shared-decision approaches rooted in evidence-based pharmacotherapeutics including the latest agents such as SGLT2-inhibitors, GLP1-receptor agonists, and PCSK9 inhibitors
⦁ Counsel and motivate diverse patient populations with culturally informed lifestyle modifications while considering social determinants of health

CME Number: H24121

Type: CME


Create or Log in to My Conference Planner to add notes.




  • AAPA Category 1 CME – 2

  • Categories


    • National Health Priority
    • Potentially Meets State Requirement(s)